Monday, January 30, 2006

Celebrex, Vioxx may reduce breast cancer risk by up to 71 percent

Newindie Press, January 31 2006
A new study has found that daily use of selective COX-2 inhibitors, such as celecoxib (Celebrex) and rofecoxib (Vioxx), reduces the risk of breast cancer by up to 71 percent.The study, by Randall Harris and colleagues from The Ohio State University College of Medicine and Public Health, Columbus, Ohio, which highlights the potential of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for the prevention of breast cancer, was based on data collected on 323 patients with invasive breast cancer shortly after their diagnosis. The researchers observed that while daily use of selective COX-2 inhibitors was associated with a 71 percent reduction in the risk of breast cancer, non-selective COX-2 inhibitors, such as aspirin and ibuprofen, also reduced the risk of breast cancer. --Click the title of this post to read the full article from its source--


Post a Comment

<< Home

/* WebRing Code */